Kestra Medical (KMTS) Revenue Surges 62.7% YoY to $24.6M; Loss Narrows

Loss Per Share (GAAP)

$0.61

Revenue

$24.6M

Loss Narrows. Kestra Medical Technologies (NASDAQ: KMTS) reported a loss of $0.61 per share for Q3 fiscal 2026, missing consensus estimates. The medical device maker posted a net loss of $34.2 million on revenue of $24.6 million. Year-over-year, the loss widened from a loss of $0.36 per share in Q3 2025.

Revenue accelerates sharply. Revenue of $24.6 million topped the $22.9 million consensus estimates, marking a 62.7% surge from $15.1 million in the year-ago quarter. The company generated gross profit of $12.9 million against a cost of revenue of $11.6 million, yielding a 52.5% gross margin. Operating loss reached $34.8 million, while adjusted EBITDA came in at negative $21.2 million. The revenue beat extends a pattern of top-line outperformance.

What to Watch: Management held its earnings call at 4:30 PM ET on March 17. Focus on commentary around the path to profitability and whether the 63% revenue growth rate is sustainable—the company needs to demonstrate operating leverage as it scales to justify the $1.23 billion market cap against widening losses.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.